3SBio

News

Pfizer has joined the ranks of those developing cancer drugs that target PD-1 and VEGF, penning a $6bn licensing deal with China's 3SBio.

Oncology

Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.